Nasal spray to treat nocturia receives FDA approval
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The FDA has approved Serenity Pharmaceuticals’ desmopressin acetate (Noctiva) nasal spray for the treatment of nocturia due to nocturnal polyuria. This is the first FDA-approved therapy for the condition, according to the company. The product is a vasopressin analogue and works by temporary decreasing urine production, which eliminates the need for the patient to urinate during sleep. The approval was based on two randomized, placebo-controlled studies that showed a significant decrease in the mean number of nocturic voids. The most common side effects of desmopressin nasal spray include nasal discomfort, nasal congestion, increased blood pressure, and low sodium levels in the blood.......

http://urologytimes.modernmedicine.com/urology-times/news/new-products-nasal-spray-treat-nocturia-receives-fda-approval
Preview
Like
Comment
Share